Articles

October 1, 2010 – The most recent clinical data from USpella, a U.S. multicenter, observational registry of patients who received percutaneous cardiac support from the Impella 2.5 device, was...

August 11, 2010 – The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs)...

The practicality and expense of maintaining patients on total artificial hearts (TAH) may be significantly impacted with the introduction of a new, investigational portable driver unit. The 13-...

New U.S. Food and Drug Administration (FDA) indications for two key heart failure device therapies may help improve survival, slow the progress of the disease and, in some cases, reverse its...

The intra-aortic balloon pumps (IABPs) have been the gold standard for minimally invasive circulatory support for 40 years, but they were joined in recent years by percutaneously deployed...

Intra-aortic balloon pumps (IABPs), introduced in the 1970s, have been considered the standard of care for short-term circulatory support for more than two decades. However, there has been a...

A 55-year-old woman with a history of heavy alcohol use, hepatitis C induced cirrhosis, hypertension, and chronic renal insufficiency presented at Massachusetts General Hospital in Boston Mass.,...

There is growing interest in going beyond using ventricular assist devices (VADs) just for end-stage heart failure and expanding use for therapeutic recovery in patients with cardiogenic shock,...